Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2023, Senti Biosciences, Inc. (the "Company") held its virtual 2023 Annual Meeting of Stockholders (the "Annual Meeting"). The proposals set forth below were submitted to the stockholders at the Annual Meeting and are further described in the Company's proxy statement.

At the Annual Meeting, the Company's stockholders: (i) elected each of the three Class I directors, Timothy Lu, M.D., Ph.D., Edward Mathers, and Omid Farokhzad, M.D., to the Company's board of directors to serve until the 2026 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal, and (ii) ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. Represented in person or by proxy at the Annual Meeting were 34,465,609 shares of the Company's common stock, out of 44,168,034 shares entitled to vote at the Annual Meeting, or 78.0% of the total number of shares outstanding as of the record date. The results of the matters submitted to a stockholder vote at the Annual Meeting were as follows.

1. Election of directors:



                   Name                    For           Withheld        Broker Non-Votes

        Timothy Lu, M.D., Ph.D.           32,295,728         81,697               2,088,184
        Edward Mathers                    22,511,863      9,865,562               2,088,184
        Omid Farokhzad, M.D.              26,184,748      6,192,677               2,088,184

2. Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023:



                              For            Against        Abstain

                           34,350,453        60,890         54,266

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses